Common side effects (affecting up to 1 in 10 people): Vomiting Constipation Abdominal pain or discomfort Dyspepsia (indigestion) Decreased appetite Hypoglycaemia (low blood sugar), particularly when used in combination with insulin or sulphonylureas Injection site reactions (redness, itching, or bruising) Less common but important side effects: Acute pancreatitis: Characterised by severe, persistent abdominal pain that may radiate to the back
Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance
While older medications like Ozempic and Wegovy only target the GLP-1 receptor, tirzepatide is the first medication to target both GLP-1 and GIP receptors
They have stability data supporting that timeline for their specific formulation
Dont let fatigue or illness slow you down
Both the American Diabetes Association and Kidney Disease Improving Global Outcomes organization provide updated pharmacological recommendations for treating T2DM in people with CKD that include the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
.png.jpg)
